Intellia Therapeutics (NASDAQ: NTLA) and CRISPR Therapeutics (NASDAQ: CRSP) have one big thing in common: They both specialize in the hot area of gene editing, or the repairing of faulty genes ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Wall Street analysts have high hopes for Intellia Therapeutics stock. The company's late-stage pipeline programs are shaping up nicely. Upcoming data readouts will need to be very impressive to hit ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...

Intellia Therapeutics has released positive data from its Phase I/II study of NTLA-2002, a CRISPR-based gene editing therapy. The study shows promising results for in vivo gene editing, offering ...

Robert W. Baird analyst Jack Allen has maintained their neutral stance on NTLA stock, giving a Hold rating yesterday. Jack Allen has given his Hold rating due to a combination of factors affecting ...

We came across a bearish thesis on Intellia Therapeutics, Inc. on X.com by A_May_MD. In this article, we will summarize the ...

Thursday was hardly a good day to be a shareholder of Intellia Therapeutics (NASDAQ: NTLA). After the biotech delivered some news from the lab and witnessed one analyst's negative reaction to it, the ...

Intellia and CRISPR Therapeutics both work in the field of gene editing. CRISPR Therapeutics just won regulatory approval for its first product, while Intellia recently entered late-stage development ...